Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Telangiectasis
Description
Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders. MeSH
Hierarchy View
Subtype Terms (4)
Ataxia Telangiectasia
28 drugs (25 approved, 3 experimental)
CREST Syndrome
2 drugs (1 approved, 1 experimental)
Retinal Telangiectasis
4 drugs (2 approved, 2 experimental)
Telangiectasia, Hereditary Hemorrhagic
17 drugs (13 approved, 4 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (1)
Phase 2 Indicated Drugs (2)
Phase 1 Indicated Drugs (1)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 2 Indications (42)
Eye Center of Northern Colorado
Feinstein Institute for Medical Research
Hereditary Hemorrhagic Telangiectasia Foundation International
LuEsther T. Mertz Retinal Research Center
Manhattan Eye, Ear & Throat Hospital
National Health and Medical Research Council, Australia
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (8)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
